Navigation Links
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting

nd demonstrated that the electroporation-enhanced immune responses to a hepatitis C DNA vaccine were capable of eliminating all liver cells that produced a model hepatitis C virus gene, simulating a potential cure of hepatitis C infection. Vaccination by methods not employing Inovio's technology were less or not effective.

Two other Inovio presentations reported electroporation device innovations including the Elgen 1000 system and a single-needle device. The Elgen 1000 system, which recently received CE marking, consists of an advanced pulse generator and a two-needle DNA injector that delivers the genes and electroporation pulses in a single step. The pulse generator allows flexible programming of pulse and injection parameters via a flash card operated personal computer, as well as comprehensive recording and storage of electroporation and patient data. The single needle device, in early development, allows injection of the DNA and electroporation with a single needle resembling a normal injection needle and applies pulses of lower voltage than those delivered by presently used devices, thus reducing the electrical sensation experienced by the patient.

"We are pleased with the performance of our DNA delivery technology in advanced preclinical studies. Together with our continuing innovations in electroporation devices, our technology may be able to make critical contributions to the development of novel, effective vaccines for the treatment or prevention of major life-threatening infectious diseases," said Dr. Avtar Dhillon, Inovio's president and CEO.

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Post Your Comments:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/5/2015)... ... ... If you are nervous about either giving or getting shots, you are ... than ever before for an idea conceived of by an inventor from Cerritos, Calif. ... and patients against accidental needle punctures. As such, it prevents surgical team members from ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... elderly Americans currently being cared for in nursing homes and assisted living facilities are ... discussed a personal story in which her father was at one point close to ...
(Date:9/4/2015)... Viejo, CA (PRWEB) , ... September 04, 2015 , ... ... click of a mouse all within Final Cut Pro X. With TransCel users have ... Adjust the frame width, background color, speed method, frame color, inner color, text, and ...
(Date:9/4/2015)... , ... September 04, 2015 , ... IVF New England, ... a New Hampshire fertility "ManchVegas Happy Hour" in Manchester for women who wish to ... 2015 at XO on Elm restaurant and lounge, 827 Elm Street, Manchester, NH from ...
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County charitable ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships to ... cancer treatments and recover their mobility, strength, and range of motion following breast ...
Breaking Medicine News(10 mins):Health News:Safety Feature for Needle Injections Invented by InventHelp Client (OCM-914) 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2
... ... 22 , ... 2010 -- Congressman James E. Clyburn will give the commencement address at the 135th Commencement ceremony ... 1 p.m. at David Lipscomb University in the Allen Arena. Doors open at 11:30 a.m., , ...
... ... of our team of Judges and Management Team, iCMG is happy ... Award competition! These international awards along with "John Zachman award for ... for significant achievements in the field of Enterprise and IT Architecture. ...
... Rockville, Md., May 10, 2010 To promote ... labelsand to address the widespread problem of patient ... the U.S. Pharmacopeial Convention (USP) recently issued a ... on dispensed prescription packaging. The recommendations are patient-centered, ...
... A study by researchers from the Georgetown Lombardi ... identifies a potential new combination therapy to "rescue" treatment ... The findings were published on May 15, 2010 ... . Fulvestrant is a common second-line therapy for ...
... Milan, Italy, 10 May 2010 Children with dyslexia ... an appropriate education and demonstrating intellectual ability in other ... difficulties with written language may be linked to structural ... known to play a role in oral language. The ...
... warranted, study finds , MONDAY, May 10 (HealthDay News) -- ... of elderly people with kidney cancer that has not spread, ... such cancer should undergo more conservative treatments that preserve the ... have increased over the past 10 years, especially among older ...
Cached Medicine News:Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3Health News:iCMG Architecture Awards for Truly Outstanding Enterprise and IT Excellence 2Health News:iCMG Architecture Awards for Truly Outstanding Enterprise and IT Excellence 3Health News:Panel recommends standardizing prescription container labeling 2Health News:Panel recommends standardizing prescription container labeling 3Health News:Panel recommends standardizing prescription container labeling 4Health News:Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells 2Health News:Differences in language circuits in the brain linked to dyslexia 2
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... Vitamin D kit is an enzymeimmunoassay for ... hydroxylated metabolites in serum or plasma. Calibrators, ... labelled 25-OH D. The diluted samples are ... with a highly specific sheep 25-OH D ...
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
... Immunoscan Anti-GBM was developed to detect ... glomerular basement membrane. The information is ... where anti-collagen (IV) - a3 chain ... pulmonary hemorrhage are primary diagnostic parameters. ...
Medicine Products: